|
NICE U-turn on Novartis' Xolair for asthma
PharmaTimes The National Institute for Health and Clinical Excellence said it now recommends Xolair (omalizumab) as an option for treating severe, persistent allergic asthma in adults, adolescents and children, in a complete turnaround from its earlier intention … Asthma treatment – double U-turn Life-changing jab gives hope to asthma sufferers NICE approves use of asthma drug omalizumab |
View full post on asthma – Google News